Calcimimetic therapy modified the radiological, surgical, and histopathological features of a parathyroid adenoma Authors: Hiroyuki Yamashita, Hisakazu Shindo, Daisuke Tatsushima, Hirokazu Kurohama, Kenichiro Koga, Masahiro Nakashima Published: 2026 ABSTRACT AbstractCalcimimetics are increasingly used to control hypercalcemia before parathyroidectomy. Although treatment-induced degenerative changes have been reported in parathyroid adenomas, their effects on preoperative imaging and surgical planning remain unclear. A 70-year-old woman with primary hyperparathyroidism was administered preoperative evocalcet (2 mg/day). After ∼2 months, serum calcium levels decreased to the hypocalcemic range, prompting drug discontinuation before surgery referral. Upon presentation, corrected serum calcium normalized to 9.1 mg/dL (SI: 2.28 mmol/L; reference range, 8.8-10.1 mg/dL [SI: 2.20-2.53 mmol/L]), whereas intact parathyroid hormone remained mildly elevated at 65.7 pg/mL (SI: 7.0 pmol/L; reference range, 10-65 pg/mL [SI: 1.1-6.9 pmol/L]). Ultrasonography revealed a right superior parathyroid lesion, with markedly decreased Doppler flow. Four-dimensional computed tomography revealed weak enhancement throughout the contrast-enhanced phase. Parathyroidectomy revealed marked fibrosis and dense adhesions around the recurrent laryngeal nerve, making dissection technically demanding, although the nerve was preserved. Histopathological examination confirmed parathyroid adenoma with extensive fibrosis, cystic degeneration, necrosis, and macrophage infiltration. Therefore, calcimimetic therapy may modify the radiological and histopathological characteristics of parathyroid adenomas and intraoperative findings relevant to surgical planning. Recognition of these treatment-induced changes may improve the interpretation of preoperative images, help surgeons anticipate dense adhesions, and facilitate meticulous surgical dissection.Keywords: primary hyperparathyroidism, evocalcet therapy, 4-dimensional computed tomography, ultrasonography, pathology Introduction Primary hyperparathyroidism (PHPT) is often caused by a solitary parathyroid adenoma, and parathyroidectomy remains the only curative treatment available. Accurate preoperative localization is essential for successful minimally invasive surgery, with ultrasonography (US), technetium-99m sestamibi (MIBI) scintigraphy, and 4-dimensional computed tomography (4D-CT) playing complementary roles in contemporary surgical practice [1]. Recently, medical management of PHPT has expanded, with various pharmacological agents, including calcimimetics, denosumab, and bisphosphonates, being increasingly used to control hypercalcemia and treat osteoporosis preoperatively [2, 3]. Although these therapies provide important clinical benefits, they may modify the clinical phenotype of PHPT, thereby complicating the diagnostic interpretation and therapeutic decision-making. We reported 2 patients in whom pharmacological therapy modified the clinical phenotype of PHPT; one in whom preoperative denosumab altered postoperative biochemical interpretation despite successful parathyroidectomy, and another in whom dienogest unmasked previously subclinical PHPT [4, 5]. These observations highlight the importance of identifying drug-induced modifications in the clinical phenotype of PHPT. Calcimimetics have become an established medical treatment for patients with PHPT who are unable or unwilling to undergo surgery and temporary control of hypercalcemia before parathyroidectomy [3, 6, 7]. By activating calcium-sensing receptors (CaSR), these agents effectively reduce serum calcium concentration without directly eliminating underlying parathyroid lesions [8, 9]. Moreover, evidence suggests that calcimimetics may induce structural remodeling in parathyroid adenomas. Previous reports involving cinacalcet have described intratumoral hemorrhage, cystic degeneration, fibrosis, and dense peritumoral adhesions [10, 11]. However, the impact of calcimimetics-induced tissue remodeling on preoperative imaging and surgical decision-making remains unclear. Here, we report the case of a patient with PHPT who underwent parathyroidectomy after preoperative evocalcet therapy. The patient demonstrated atypical imaging findings, marked intraoperative fibrosis with dense adhesions to the recurrent laryngeal nerve, and extensive degenerative histopathological changes. This case illustrates the influence of calcimimetics-induced tissue remodeling on preoperative imaging interpretation and surgical decision-making, thereby modifying the clinical phenotype of PHPT. Case presentation A 70-year-old woman was referred to our institution for surgical treatment of PHPT. Based on persistent hypercalcemia and elevated serum parathyroid hormone (PTH) concentrations, asymptomatic PHPT was diagnosed. Upon diagnosis, serum corrected calcium was 10.4 mg/dL (SI: 2.60 mmol/L; reference range, 8.8-10.1 mg/dL [SI: 2.20-2.53 mmol/L]), and intact PTH was 139 pg/mL (SI: 14.8 pmol/L; reference range, 10-65 pg/mL [SI: 1.1-6.9 pmol/L]). Because the hypercalcemia was relatively mild, the patient was managed conservatively at the referring hospital. Although serum calcium levels remained unchanged during follow-up, treatment with evocalcet (2 mg daily) was initiated at the patient's request for medical treatment. After 2 months of treatment, serum corrected calcium decreased to the hypocalcemic range (7.8 mg/dL, SI: 1.95 mmol/L), and evocalcet was discontinued. Although evocalcet reduced the serum calcium concentration, the patient strongly desired definitive treatment rather than continued medical therapy and was referred to our institution for a parathyroidectomy. Diagnostic assessment The patient visited our clinic 1 week after stopping evocalcet; serum corrected calcium level was 9.1 mg/dL (2.28 mmol/L), whereas intact PTH remained mildly elevated (66 pg/mL, SI: 6.97 pmol/L). Following medical treatment, bone mineral density was 80% of the young adult mean at the lumbar spine and 90% at the total radius, and CT showed no nephrolithiasis. Neck US performed 2 years preoperatively at the referring hospital demonstrated a 13 mm hypoechoic lesion posterior to the upper pole of the right thyroid lobe with detectable intralesional Doppler flow (Fig. 1A). At our institution, repeat US identified an ∼11 mm hypoechoic lesion at the same location, with markedly decreased intralesional Doppler flow (Fig. 1B). The MIBI scintigraphy performed at the referring hospital revealed focal tracer uptake corresponding to the lesion. Four-dimensional CT identified the lesion; however, it demonstrated weak enhancement in the arterial and delayed phases (Fig. 1C and 1D). During the study period, 4D-CT was systematically performed as part of our institutional preoperative localization protocol to evaluate the diagnostic performance of US, sestamibi scintigraphy, and 4D-CT. Based on biochemical findings and localization studies, a solitary right superior parathyroid adenoma was diagnosed, and focused parathyroidectomy was planned. Preoperative imaging findings. (A) Ultrasonography performed 2 years preoperatively at the referring hospital reveals a 13 mm hypoechoic lesion with detectable intralesional Doppler flow posterior to the upper pole of the right thyroid lobe (arrow), consistent with a parathyroid adenoma. (B) Preoperative ultrasonography shows an 11 mm hypoechoic lesion in the same location, with markedly decreased intralesional Doppler flow. (C, D) Contrast-enhanced computed tomography demonstrates a lesion (arrows). Unlike the typical imaging appearance of untreated parathyroid adenomas, the lesion shows no significant enhancement in the arterial and venous phases. Treatment Focused parathyroidectomy was performed using intraoperative recurrent laryngeal nerve monitoring, because preoperative imaging suggested that the lesion was located close to the nerve. The enlarged right superior parathyroid gland was densely adhered to the posterior thyroid capsule and surrounding tissues, including the area adjacent to the recurrent laryngeal nerve. Although the nerve was successfully preserved and the gland was completely removed, dissection was technically demanding. Hemostasis around the Berry ligament was challenging, and the operative time was 92 minutes, which is considerably longer than the required time (30 minutes) for a lesion of comparable size at our institution. Macroscopic examination revealed an enlarged parathyroid gland, weighing 412 mg (Fig. 2A). Histopathological examination revealed a parathyroid adenoma surrounded by a thick fibrous capsule with cystic degeneration, necrosis, macrophage infiltration, spindle-shaped tumor cells, and mild-to-moderate nuclear atypia (Fig. 2B and 2C). There was no evidence of capsular or extraglandular invasion. The pathologists considered these findings to represent treatment-related tissue remodeling associated with previous calcimimetic therapy. Histopathological findings. (A) Gross appearance of the resected parathyroid adenoma shows a relatively thick whitish capsule and focal cystic degeneration (412 mg). (B) Low-power hematoxylin and eosin staining shows a thick fibrous capsule (arrow) surrounding the adenoma with extensive cystic degeneration (arrowhead). (C) High-power view demonstrating predominantly oxyphil cells with focal spindle-cell change (arrow) and mild nuclear atypia. Overall, the histopathological findings are compatible with the treatment-related modifications associated with previous calcimimetic therapy. Outcome and follow-up Postoperative serum levels normalized without complications. At the final follow-up visit 3 months postoperatively, the corrected calcium and PTH levels were 9.4 mg/dL (2.35 mmol/L) and 39 pg/mL (4.1 pmol/L), respectively. Discussion Calcimimetics have become an established medical treatment for PHPT in patients awaiting surgery or those who are not candidates for immediate surgery [3, 6, 7]. Their principal mechanism is the activation of the CaSR, which results in the suppression of PTH secretion and reduction of serum calcium concentrations [8, 9]. Although there are currently no reports specific to evocalcet, previous studies on cinacalcet by Di Dalmazi et al [10] and Werner et al [11] suggest that CaSR-mediated cellular apoptosis and subsequent tissue necrosis can trigger regressive morphological changes, including cystic degeneration, inflammatory infiltration, and fibrosis. Therefore, the histopathological alterations observed in our patient are speculated to stem from a similar class effect of CaSR activation. This case extends these observations by demonstrating concordant vascular imaging abnormalities and operative difficulties following preoperative evocalcet therapy. Pathological changes may increase the operative difficulty and occasionally mimic malignant diseases. Comparable descriptions of evocalcet therapy are extremely limited. Here, the adenoma exhibited extensive fibrosis, cystic degeneration, focal necrosis, hemosiderin deposition, and macrophage infiltration, suggesting that evocalcet may induce tissue remodeling similar to that reported with cinacalcet [10, 11] and this phenomenon may represent a class effect of calcimimetic therapy. The most distinctive finding was the atypical appearance on imaging scans. Compared with untreated parathyroid adenomas, which typically demonstrate avid arterial enhancement on 4D-CT, the lesion showed weak enhancement throughout the contrast-enhanced phase and markedly decreased internal vascularity on Doppler US. These imaging results were consistent with the extensive fibrosis and cystic degeneration observed histologically, suggesting a treatment-induced reduction in intratumoral vascularity. This observation has important implications for preoperative localization. As color Doppler US and 4D-CT rely on the characteristic vascularity of parathyroid adenomas, a treatment-induced reduction in intratumoral vascularity may diminish Doppler flow signals and contrast enhancement, thereby reducing lesion conspicuity. To our knowledge, the effects of preoperative calcimimetic therapy on vascular imaging findings, including color Doppler US and contrast-enhanced CT, have not previously been reported. Recognition of previous calcimimetic therapy may facilitate interpretation of these atypical imaging findings and improve surgical planning. The operative findings further support the possibility of treatment-induced tissue remodeling. Despite the relatively small size of the adenoma, extensive fibrosis and dense adhesions obscure the normal tissue planes, substantially increasing the technical complexity of parathyroidectomy. Although dense adhesions may raise concerns for locally invasive disease, they should be interpreted cautiously in patients who have received calcimimetic therapy because treatment-induced tissue remodeling may produce similar operative findings. This phenomenon may help surgeons anticipate technically demanding dissections while avoiding overinterpretation of adhesions as evidence of malignancy. This study has several limitations. This represents a single-patient observation, and direct causality between evocalcet therapy and the observed imaging, operative, and pathological findings cannot be established. Additionally, pretreatment 4D-CT was unavailable, preventing a direct comparison of the enhancement characteristics pre- and post-therapy. However, the remarkable concordance among atypical imaging findings, severe operative fibrosis, and extensive degenerative pathological changes strongly supports the possibility of treatment-related remodeling. Notably, serum calcium normalized with only mildly elevated PTH levels after evocalcet discontinuation. Along with the marked degenerative changes observed histologically, these findings raise the hypothesis that prolonged calcimimetic therapy may influence adenoma viability and long-term secretory capacity. In conclusion, preoperative evocalcet therapy may modify the biochemical profile and radiological, surgical, and histopathological phenotypes of parathyroid adenomas. Awareness of previous calcimimetic therapy may improve the interpretation of preoperative images, facilitate appropriate surgical decision-making, and help surgeons anticipate technically demanding dissections. Calcimimetics should be regarded as agents that lower serum calcium levels and biological modifiers that may alter the clinical phenotype of PHPT. Learning points Calcimimetic therapy may modify biochemical, radiological, surgical, and histopathological phenotypes of PHPT. Calcimimetic therapy may modify biochemical, radiological, surgical, and histopathological phenotypes of PHPT. Reduced Doppler vascularity and weak contrast enhancement after calcimimetic therapy should be interpreted considering previous calcimimetic exposure. Reduced Doppler vascularity and weak contrast enhancement after calcimimetic therapy should be interpreted considering previous calcimimetic exposure. Although calcimimetics effectively control hypercalcemia, their potential effect on subsequent imaging interpretation and surgical management should be considered before initiating therapy. Although calcimimetics effectively control hypercalcemia, their potential effect on subsequent imaging interpretation and surgical management should be considered before initiating therapy. Contributors All authors have made individual contributions to authorship. H.Y., H.S., D.T., and K.K. diagnosed and managed the patient and contributed to the clinical interpretation of the case. H.K. and M.N. provided critical intellectual input regarding the pathophysiology of the case. All authors contributed to the interpretation of the findings, critical revision of the manuscript for important intellectual content, and approval of the final version. Abbreviations 4-dimensional computed tomography calcium-sensing receptors primary hyperparathyroidism parathyroid hormone ultrasonography Contributor Information Hiroyuki Yamashita, Department of Surgery, Yamashita Thyroid Hospital, Fukuoka 812-0034, Japan. Hisakazu Shindo, Department of Surgery, Yamashita Thyroid Hospital, Fukuoka 812-0034, Japan. Daisuke Tatsushima, Department of Surgery, Yamashita Thyroid Hospital, Fukuoka 812-0034, Japan. Hirokazu Kurohama, Department of Tumor and Diagnostic Pathology, Atomic Bomb Disease Institute, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki 852-8523, Japan. Kenichiro Koga, Kokura Thyroid and Breast Clinic, Kitakyushu 802-0081, Japan. Masahiro Nakashima, Department of Tumor and Diagnostic Pathology, Atomic Bomb Disease Institute, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki 852-8523, Japan. Funding No public or commercial funding was received for this study. Disclosures None declared. Informed patient consent for publication Signed informed consent obtained directly from the patient. Data availability Data sharing is not applicable to this article, as no datasets were generated or analyzed in the current study. References Associated Data Data Availability Statement Data sharing is not applicable to this article, as no datasets were generated or analyzed in the current study.